ストックスクリーナーアプリを入手
4.95
2.37%
-0.12
アフターアワーズ：
4.99
0.04
+0.81%
前日終値:
$5.07
開ける：
$4.93
24時間の取引高:
435.67K
Relative Volume:
0.29
時価総額：
$159.37M
収益：
-
当期純損益:
$-29.25M
株価収益率:
-4.292
EPS:
-1.1533
ネットキャッシュフロー:
$-22.80M
1週間 パフォーマンス:
+12.76%
1か月 パフォーマンス:
+9.51%
6か月 パフォーマンス:
+27.25%
1年 パフォーマンス:
-7.99%
1日の値動き範囲:
$4.92
$5.25
1週間の範囲:
$4.85
$6.44
52週間の値動き範囲:
$2.39
$20.71
Sagimet Biosciences Inc Stock (SGMT) Company Profile
名前
Sagimet Biosciences Inc
セクター
電話
(650) 561-8600
住所
155 BOVET RD., SUITE 303, SAN MATEO
SGMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
4.95 | 159.37M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | Oppenheimer | Outperform |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-06-28 | ダウングレード | Goldman | Buy → Neutral |
| 2024-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-25 | 開始されました | Leerink Partners | Outperform |
| 2023-08-08 | 開始されました | Goldman | Buy |
| 2023-08-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-08 | 開始されました | Piper Sandler | Overweight |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
すべてを表示
Sagimet Biosciences Inc (SGMT) 最新ニュース
Sagimet Biosciences: A Rising Star in the Fight Against NASH with Promising Clinical Data for Denifanstat - mediahousepress
Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com Australia
Sagimet Biosciences up 30% on strong clinical stage data - Mugglehead
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
(SGMT) On The My Stocks Page - Stock Traders Daily
Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at Oppenheimer - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Oppenheimer - MarketBeat
Oppenheimer Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited (NASDAQ:SGMT) - Seeking Alpha
Oppenheimer sets $30 target on Sagimet Biosciences shares - Investing.com
How To Trade (SGMT) - Stock Traders Daily
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Sagimet Biosciences to Present at Piper Sandler Healthcare Conference | SGMT Stock News - StockTitan
Sagimet Biosciences participates ik,on No - TipRanks
Sagimet Biosciences Inc. Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDthe Liver Meeting 2024 - Marketscreener.com
HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com
Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDThe Liver Meeting® 2024 - The Manila Times
Sagimet Biosciences Presents Clinical Denifanstat and - GlobeNewswire
Sagimet's Denifanstat Shows 49% Fibrosis Improvement in Phase 2b MASH Trial | SGMT Stock News - StockTitan
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Sagimet Biosciences' (SGMT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Steven Cohen's Strategic Acquisition in Sagimet Biosciences Inc - GuruFocus.com
Hillhouse Capital Management's Strategic Reduction in Sagimet Bi - GuruFocus.com
Baker Bros. Advisors LP Increases Stake in Sagimet Biosciences I - GuruFocus.com
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $24.00 Consensus Price Target from Analysts - Defense World
Sagimet Biosciences Advances MASH Treatment with Denifanstat - TipRanks
Sagimet: More Than Just A MASH Drug Development Biotech (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences reports Q3 EPS (45c) vs (35c) last year - TipRanks
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sagimet's Denifanstat Earns FDA Breakthrough Status; Reports $170M Cash Position | SGMT Stock News - StockTitan
Ascletis Completes Enrollment of Phase III Trial of ASC40 Once-Daily Oral Tablet for Treatment of Acne - Marketscreener.com
UBS says Sagimet stock could steal the MASH spotlight from injectables - Investing.com Canada
Sagimet stock draws buy at UBS on MASH(SGMT:NASDAQ) - Seeking Alpha
SGMTSagimet Biosciences Inc. Series A Latest Stock News & Market Updates - StockTitan
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Price Target at $24.00 - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS Group - MarketBeat
Sagimet Biosciences initiated with a Buy at UBS - TipRanks
Sagimet Biosciences Insiders Benefit From Selling Stock At US$3.10 - Simply Wall St
Trend Tracker for (SGMT) - Stock Traders Daily
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference - The Manila Times
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News
Sagimet Biosciences Inc (SGMT) 財務データ
収益
当期純利益
現金流量
EPS
Sagimet Biosciences Inc (SGMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 19 '24 |
Sale |
3.10 |
8,357 |
25,910 |
81,213 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 19 '24 |
Sale |
3.10 |
10,914 |
33,830 |
160,506 |
| Kemble George | Executive Chairman |
Jul 19 '24 |
Sale |
3.10 |
14,062 |
43,605 |
142,318 |
| Happel David | President & CEO |
Mar 26 '24 |
Buy |
5.27 |
12,100 |
63,731 |
639,200 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):